Abstracts Archive - Page 2169 of 2425 - ACR Meeting Abstracts

Abstract Number: 1224 • 2013 ACR/ARHP Annual Meeting
Prednisone Has No Effect On Odanacatib Pharmacokinetics In Healthy Subjects
Gene Marcantonio¹, Chengcheng Liu², Stefan Zajic³, Chantal Mahon², David Hreniuk², Anish Mehta⁴, Kate Mostoller², Denise Morris⁵, Hongwei Xue⁵ and S. Aubrey Stoch², ¹Merck & Co., Whitehouse Station, NJ, ²Merck Sharp & Dohme Corp., Whitehouse Station, NJ, ³Merck Sharp & Dohme Corp, Whitehouse Station, NJ, ⁴Merck Sharp & Dohme Corp.,, Whitehouse Station, NJ, ⁵Covance, Madison, WI
Background/Purpose: We evaluated the effect of prednisone, a glucocorticoid believed to induce the CYP P450 enzyme, on the pharmacokinetics of odanacatib, a novel Cathepsin K…
Abstract Number: 1225 • 2013 ACR/ARHP Annual Meeting
FRAX 10-Year Fracture Risk In Women With a Fracture Of The Distal Forearm: Agreement Between Assessments With and Without Bone Mineral Density and Influence Of Measurement Side In Individual Patients
Emilie Egsmose¹, Mette Birkvig², Thora Buhl³ and Ole Rintek Madsen³, ¹Copenhagen University Hospital Hvidovre, Copenhagen, Denmark, ²Osteoporosis Clinic, Copenhagen University Hospital Gentofte, Copenhagen, Denmark, ³Copenhagen University Hospital Gentofte, Copenhagen, Denmark
Background/Purpose: The FRAX® tool has been developed by WHO to evaluate fracture (Fx) risk of patients. It is based on individual patient models that integrate…
Abstract Number: 1226 • 2013 ACR/ARHP Annual Meeting
Adherence With Current Osteoporosis Treatment Guidelines Among Rheumatologists Caring For Patients With Rheumatoid Arthritis Using Items From The Fracture Risk Assessment Tool Score
Jennifer Watt¹, Andrew E. Thompson², Nicole G. H. Le Riche³ and Janet E. Pope⁴, ¹Medicine, University of Western Ontario, London, ON, Canada, ²Rheumatology, St. Josephs Health Ctr, London, ON, Canada, ³Department of Medicine, St. Joseph's Hospital, London, ON, Canada, ⁴Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: To assess whether the Fracture Risk Assessment Tool (FRAX) score in patients with RA correlates with likelihood of osteoporosis (OP) prescription including drug treatment,…
Abstract Number: 1228 • 2013 ACR/ARHP Annual Meeting
Trabecular BONE Score In Rheumatoid Arthritis and Ankylosing Spondylitis and Changes During LONG TERM Treatment With TNFA Blocking Agents
Eric Toussirot¹, Laurent Mourot², Daniel Wendling³, Gilles Dumoulin⁴ and CIC BT⁵, ¹Université de Franche Comté , CHRU, CIC Biotherapy 506 and Rheumatology and EA 4266 Pathogens and Inflammation, Besançon, France, ²CIC-It, University of Franche Comté, Besançon, France, ³Rheumatology, University Hospital, Besancon, France, ⁴University hospital, Department of Endocrine and Metabolic Biochemistry, Besançon, France, ⁵CIC BT, University Hospital, Besançon, France
Background/Purpose: Inflammatory rheumatic diseases such as rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are associated with osteoporosis. Bone mass in RA and AS has been…
Abstract Number: 1229 • 2013 ACR/ARHP Annual Meeting
A Before and After Comparison Of The Effects Of Monitoring On a Quality Indicator For glucocorticoid–induced Osteoporosis In a Japanese Hospital
Yasuhiro Suyama¹, Mitsumasa Kishimoto¹, Chisun Min², Yoichiro Haji¹, Yuri Ohara¹, Ryo Rokutanda¹, Hisanori Shimizu¹, Ken-ichi Yamaguchi³, Yukio Matsui³ and Masato Okada³, ¹Division of Allergy & Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ²Division of Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ³Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is one of the most devastating side effects of glucocorticoid use, leading to a substantially increased risk of fracture and disability…
Abstract Number: 1231 • 2013 ACR/ARHP Annual Meeting
The Quality Of Life and Resource Use Related To Hip Fractures Based On Data From The International Costs and Utilities Related To Osteoporotic Fractures Study
Moa Ivergård¹, Viktor Wintzell¹, László B Tankó², Victoria Barghout³, Axel Svedbom¹, Vidmantas Alekna⁴, Maria Luisa Bianchi⁵, Patricia Clark⁶, Manuel Díaz Curiel^7,8, Hans Peter Dimai⁹, Mikk Jürisson¹⁰, Olga Lesnyak¹¹, Eugene McCloskey¹², Kerrie M Sanders¹³, Thierry Thomas¹⁴, Fredrik Borgström¹⁵ and John A Kanis¹⁶, ¹OptumInsight, Stockholm, Sweden, ²Novartis Pharma AG, Basel, Switzerland, ³VEB HealthCare, Morristown, NJ, ⁴Vilnius University, Faculty of Medicine, Vilnius, Lithuania, ⁵Bone Metabolism Unit, Istituto Auxologico Italiano IRCCS, Milan, Italy, ⁶Clinical Epidemiology Unit, Hospital Infantil Federico Gómez and Faculty of Medicine UNAM, Mexico City, Mexico, ⁷Servicio de Medicina Interna/Enfermedades Metabolicas Osea, Fundacion Jimenez Diaz, Madrid, Spain, ⁸Catedra de Enfermedades Metabolicas Óseas, Universidad Autonoma, Madrid, Spain, ⁹Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria, ¹⁰Department of Public Health, Faculty of Medicine, Tartu University, Tartu, Estonia, ¹¹Ural State Medical Academy, Yekaterinburg, Russia, ¹²Academic Unit of Bone Metabolism, Metabolic Bone Centre, University of Sheffield, Sheffield, United Kingdom, ¹³Department of Medicine, NorthWest Academic Centre, The University of Melbourne, Melbourne, Australia, ¹⁴INSERM U1059, CHU-St-Etienne, Saint Etienne, France, ¹⁵LIME/MMC, Karolinska Institutet, Stockholm, Sweden, ¹⁶WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, United Kingdom
Background/Purpose: The International Costs and Utilities Related to Osteoporotic fractures Study (ICUROS) is an ongoing 18 months prospective observational study with the objective of estimating…
Abstract Number: 1232 • 2013 ACR/ARHP Annual Meeting
Osteoporosis In Rheumatoid Arthritis – Still a Threat In The Biologic Era?
Glenn Haugeberg¹, Torhild Garen², Hege Sommerseth³, Anne Prøven³ and Knut Helgetveit³, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ³Rheumatology, Martina Hansens Hospital, Bærum, Norway
Background/Purpose: Osteoporosis is a well-known extra articular manifestation in rheumatoid arthritis (RA). In RA biologic disease modifying anti rheumatic drugs (DMARDs) has been shown to…
Abstract Number: 1233 • 2013 ACR/ARHP Annual Meeting
Strontium Ranelate Uncouples Bone Resorption From Bone Formation In Osteoporotic Patients With Or Without Clinical Risk Factors
Olivier Bruyere¹, Julien Collette² and Jean-Yves Reginster¹, ¹Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium, ²University of Liege, Labo RIA, CHU Sart Tilman, Liege, Belgium
Background/Purpose: Strontium ranelate has proven efficacy against vertebral and nonvertebral fractures in postmenopausal osteoporosis. We explored whether the effect of strontium ranelate on bone turnover…
Abstract Number: 1234 • 2013 ACR/ARHP Annual Meeting
Effects Of Biological Therapy In Bone Metabolism In Patients With Chronic Inflammatory Arthropathies
Maria Victoria Hernández¹, Andrea Cuervo², Pilar Peris¹, Ana Monegal¹, Raimon Sanmarti¹, Juan D. Cañete¹ and Nuria Guañabens¹, ¹Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ²Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose: The efficacy of biological agents in the treatment of chronic inflammatory arthropathies is well known, however, the effect of this therapy in bone metabolism…
Abstract Number: 1194 • 2013 ACR/ARHP Annual Meeting
Enhanced IL-1β and IL-6 Production In Gout Patients Upon Stimulation With Mono Sodium Urate Crystals and Synergizing Agents Compared To Healthy Volunteers
Tania O. Crisan¹, Maartje Cleophas¹, Mihai G. Netea¹, Tim L. Jansen² and Leo A. Joosten³, ¹Department of Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
Background/Purpose: Gout is an autoinflammatory disease characterized by the deposition of monosodium urate (MSU) crystals in the joints of hyperuricaemic patients and subsequent attacks of…
Abstract Number: 1195 • 2013 ACR/ARHP Annual Meeting
Sex Differences In Gout Evaluation and Management
Leslie R. Harrold¹, Carol Etzel², Allan Gibofsky³, Joel M. Kremer⁴, Michael H. Pillinger⁵, Kenneth G. Saag⁶, Naomi Schlesinger⁷, Robert Terkeltaub⁸, Vanessa Cox² and Jeffrey D. Greenberg⁹, ¹University of Massachusetts Medical School, Worcester, MA, ²CORRONA, Inc, Southborough, MA, ³Medicine and Public Health, Hospital for Special Surgery, New York, NY, ⁴Center for Rheumatology, Albany Medical College, Albany, NY, ⁵NYU School of Medicine, Division of Rheumatology, New York, NY, ⁶Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁷Medicine, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, ⁸Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ⁹Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY
Background/Purpose: Little is known regarding the evaluation, characteristics and management of women with gout. To characterize potential gender differences, we therefore compared clinical manifestations and…
Abstract Number: 1196 • 2013 ACR/ARHP Annual Meeting
Chronic Renal Injury Does Not Prevent Achievement Of Target Serum Uric Acid In Tophaceous Gout
Mireille Aujero¹, J. Steuart Richards², Carl A. Nunziato³, David D. Maron⁴ and Gail S. Kerr⁵, ¹Rheuamtology Section, Washington DC VA Medical Center and Georgetown University, Washington, DC, ²Rheumatology, Washington DC VA and Georgetown University, Washington, DC, ³Rheumatology, Washington DC VA and Howard University, Howard University Hospital, Washington, DC, ⁴Research Department, Washington DC VA Medical Center, Washington, DC, ⁵Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC
Background/Purpose: ACR 2012 management guidelines for tophaceous gout (TG) recommend urate lowering therapies (ULT) to achieve a target serum uric acid (SUA) of < 6.0…
Abstract Number: 1197 • 2013 ACR/ARHP Annual Meeting
Gout Medications and The Risk For Incident Coronary Heart Disease and Stroke: The Framingham Heart Study
Weiqi Wang¹, Vidula Bhole² and Eswar Krishnan³, ¹medicine, stanford university, palo alto, CA, ²EpiSolutions Consultancy Services, Thane, India, ³Medicine, Stanford University, Palo Alto, CA
Background/Purpose: Recent studies suggest a protective association between both urate lowering medications and colchicine and the risk for coronary heart disease. The goal of the…
Abstract Number: 1198 • 2013 ACR/ARHP Annual Meeting
Allopurinol Dose Above Creatinine Clearance Based Dose Is Safe and Effective in Gout – Compliance, Efficacy and Safety At 2 and 3 Years
Nicole Coman-Wright¹, Peter T. Chapman², John L. O'Donnell³ and Lisa K. Stamp⁴, ¹Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Rheumatology, Immunology & Allergy, Christchurch Hospital, Christchurch, New Zealand, ³Rheumatology Immunology & Allergy, Canterbury Health Laboratories, Christchurch, New Zealand, ⁴University of Otago, Christchurch, New Zealand
Background/Purpose: Gout is a common form of inflammatory arthritis caused by the crystallisation of uric acid. Sustained reduction of SU below 6mg/dl is critical for…
Abstract Number: 1199 • 2013 ACR/ARHP Annual Meeting
The Performance Of a Novel Scoring System In The Differential Diagnosis Between Acute Gout and Septic Arthritis
Jung-Soo Song¹, Kwang-Hoon Lee², Sang Tae Choi¹, Eun-Jin Kang³ and You-Jung Ha⁴, ¹Rheumatology, Chung-Ang University College of Medicine, Seoul, South Korea, ²Dongguk University Ilsan Hospital, Goyang, South Korea, ³Rheumatology, Busan Medical Center, Busan, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Recently, a novel scoring system was developed for the diagnosis of gout without joint fluid analysis (1). The performance of this scoring system in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].